Insights

Why Moderna Trounced the Market on Tuesday

What happened
On Tuesday, investors were clearly feeling confident about Moderna’s (NASDAQ: MRNA) looming earnings release. On the day before the high-profile biotech was to unveil its first-quarter results, its shares rose by over 3% — thanks largely to the performance of an equally famous peer.
So what
That peer is fellow coronavirus stock Pfizer, whose results have been greatly bolstered by Comirnaty, the COVID-19 vaccine it developed with German biotech BioNTech. On Tuesday morning, Pfizer reported operational revenue growth of 82% year over year for the first quarter, and sales of Comirnaty were a key factor driving that gain.
Image source: Getty Images.

What’s good for Pfizer is good for other top COVID-19 vaccine sellers. Moderna’s mRNA-1273 — aka Spikevax — is another go-to jab, so it absolutely fits the bill. While in the U.S., we appear to be shifting out of the intense, pandemic phase of this health crisis, the coronavirus remains a threat. With products like Spikevax and Comirnaty, we can continue to fight it effectively. 
Pfizer’s ongoing strong sales of Comirnaty show that countries around the world are still eager to load up on COVID-19 shots. These products clearly have a long sales runway ahead of them.
Investors, though, should also keep in mind that Spikevax is still Moderna’s only commercialized product. By contrast, Pfizer is a pharmaceutical industry powerhouse with a great many products on the market. Moderna’s fortunes, for now, remain far more closely tied to demand for COVID-19 inoculations.
Now what
Moderna is scheduled to unveil its first-quarter results before the market opens on Wednesday. The company will also host an earnings call to discuss its performance.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy. –

What happened

On Tuesday, investors were clearly feeling confident about Moderna‘s (NASDAQ: MRNA) looming earnings release. On the day before the high-profile biotech was to unveil its first-quarter results, its shares rose by over 3% — thanks largely to the performance of an equally famous peer.

So what

That peer is fellow coronavirus stock Pfizer, whose results have been greatly bolstered by Comirnaty, the COVID-19 vaccine it developed with German biotech BioNTech. On Tuesday morning, Pfizer reported operational revenue growth of 82% year over year for the first quarter, and sales of Comirnaty were a key factor driving that gain.

Image source: Getty Images.

What’s good for Pfizer is good for other top COVID-19 vaccine sellers. Moderna’s mRNA-1273 — aka Spikevax — is another go-to jab, so it absolutely fits the bill. While in the U.S., we appear to be shifting out of the intense, pandemic phase of this health crisis, the coronavirus remains a threat. With products like Spikevax and Comirnaty, we can continue to fight it effectively. 

Pfizer’s ongoing strong sales of Comirnaty show that countries around the world are still eager to load up on COVID-19 shots. These products clearly have a long sales runway ahead of them.

Investors, though, should also keep in mind that Spikevax is still Moderna’s only commercialized product. By contrast, Pfizer is a pharmaceutical industry powerhouse with a great many products on the market. Moderna’s fortunes, for now, remain far more closely tied to demand for COVID-19 inoculations.

Now what

Moderna is scheduled to unveil its first-quarter results before the market opens on Wednesday. The company will also host an earnings call to discuss its performance.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!